Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
United States
Arizona Liver Health, Chandler, Arizona Southern California Research Center, Coronado, California Tandem Clinical Research, Marrero, Louisiana Mayo Clinic, Rochester, Minnesota Cleveland Clinic, Cleveland, Ohio University of Pennsylvania, Philadelphia, Pennsylvania Methodist Health System, Dallas Medical Center, Dallas, Texas VA North Texas Healthcare System, Dallas, Texas Texas Liver Institute, San Antonio, Texas